Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Tumor-infiltrating lymphocytes in breast cancer: ready for prime time?

Ocaña A, Diez-Gónzález L, Adrover E, Fernández-Aramburo A, Pandiella A, Amir E.

J Clin Oncol. 2015 Apr 10;33(11):1298-9. doi: 10.1200/JCO.2014.59.7286. Epub 2015 Mar 9. No abstract available.

PMID:
25753437
2.

Tumor-infiltrating lymphocytes in triple-negative breast cancer: a biomarker for use beyond prognosis?

Tsoutsou PG, Bourhis J, Coukos G.

J Clin Oncol. 2015 Apr 10;33(11):1297-8. doi: 10.1200/JCO.2014.59.2808. Epub 2015 Mar 9. No abstract available.

PMID:
25753438
3.
4.

Reply to A. Ocaña et al and P.G. Tsoutsou et al.

Loi S.

J Clin Oncol. 2015 Apr 10;33(11):1299-300. doi: 10.1200/JCO.2014.59.9423. Epub 2015 Mar 9. No abstract available.

PMID:
25753442
5.

Glutaminase expression is a poor prognostic factor in node-positive triple-negative breast cancer patients with a high level of tumor-infiltrating lymphocytes.

Kim JY, Heo SH, Choi SK, Song IH, Park IA, Kim YA, Park HS, Park SY, Bang WS, Gong G, Lee HJ.

Virchows Arch. 2017 Apr;470(4):381-389. doi: 10.1007/s00428-017-2083-5. Epub 2017 Feb 9.

PMID:
28185053
6.

Interobserver reproducibility of tumor-infiltrating lymphocyte evaluations in breast cancer.

Cabuk FK, Aktepe F, Kapucuoglu FN, Coban I, Sarsenov D, Ozmen V.

Indian J Pathol Microbiol. 2018 Apr-Jun;61(2):181-186. doi: 10.4103/IJPM.IJPM_131_17.

7.

ADAR1 expression is associated with tumour-infiltrating lymphocytes in triple-negative breast cancer.

Song IH, Kim YA, Heo SH, Park IA, Lee M, Bang WS, Park HS, Gong G, Lee HJ.

Tumour Biol. 2017 Oct;39(10):1010428317734816. doi: 10.1177/1010428317734816.

PMID:
29022489
8.

Interobserver Agreement Between Pathologists Assessing Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer Using Methodology Proposed by the International TILs Working Group.

Swisher SK, Wu Y, Castaneda CA, Lyons GR, Yang F, Tapia C, Wang X, Casavilca SA, Bassett R, Castillo M, Sahin A, Mittendorf EA.

Ann Surg Oncol. 2016 Jul;23(7):2242-8. doi: 10.1245/s10434-016-5173-8. Epub 2016 Mar 10.

PMID:
26965699
9.

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.

Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, Kellokumpu-Lehtinen PL, Bono P, Kataja V, Desmedt C, Piccart MJ, Loibl S, Denkert C, Smyth MJ, Joensuu H, Sotiriou C.

Ann Oncol. 2014 Aug;25(8):1544-50. doi: 10.1093/annonc/mdu112. Epub 2014 Mar 7.

PMID:
24608200
10.

Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.

Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ, Wolff AC, Wood WC, Davidson NE, Sledge GW, Sparano JA, Badve SS.

J Clin Oncol. 2014 Sep 20;32(27):2959-66.

11.

Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer.

Pruneri G, Vingiani A, Bagnardi V, Rotmensz N, De Rose A, Palazzo A, Colleoni AM, Goldhirsch A, Viale G.

Ann Oncol. 2016 Feb;27(2):249-56. doi: 10.1093/annonc/mdv571. Epub 2015 Nov 23.

PMID:
26598540
12.

Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers.

Krishnamurti U, Wetherilt CS, Yang J, Peng L, Li X.

Hum Pathol. 2017 Jun;64:7-12. doi: 10.1016/j.humpath.2017.01.004. Epub 2017 Jan 30.

PMID:
28153508
13.

Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer.

Li M, Li A, Zhou S, Xu Y, Xiao Y, Bi R, Yang W.

BMC Cancer. 2018 Jan 2;18(1):4. doi: 10.1186/s12885-017-3916-y.

14.

The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).

Tomioka N, Azuma M, Ikarashi M, Yamamoto M, Sato M, Watanabe KI, Yamashiro K, Takahashi M.

Breast Cancer. 2018 Jan;25(1):34-42. doi: 10.1007/s12282-017-0781-0. Epub 2017 May 9.

PMID:
28488168
15.

The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer.

Mori H, Kubo M, Yamaguchi R, Nishimura R, Osako T, Arima N, Okumura Y, Okido M, Yamada M, Kai M, Kishimoto J, Oda Y, Nakamura M.

Oncotarget. 2017 Feb 28;8(9):15584-15592. doi: 10.18632/oncotarget.14698.

16.

Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer.

Ingold Heppner B, Untch M, Denkert C, Pfitzner BM, Lederer B, Schmitt W, Eidtmann H, Fasching PA, Tesch H, Solbach C, Rezai M, Zahm DM, Holms F, Glados M, Krabisch P, Heck E, Ober A, Lorenz P, Diebold K, Habeck JO, Loibl S.

Clin Cancer Res. 2016 Dec 1;22(23):5747-5754. Epub 2016 May 17.

17.

Expression of NY-ESO-1 in Triple-Negative Breast Cancer Is Associated with Tumor-Infiltrating Lymphocytes and a Good Prognosis.

Lee HJ, Kim JY, Song IH, Park IA, Yu JH, Gong G.

Oncology. 2015;89(6):337-44. doi: 10.1159/000439535. Epub 2015 Sep 29.

PMID:
26413775
19.

Expression of the MHC class II in triple-negative breast cancer is associated with tumor-infiltrating lymphocytes and interferon signaling.

Park IA, Hwang SH, Song IH, Heo SH, Kim YA, Bang WS, Park HS, Lee M, Gong G, Lee HJ.

PLoS One. 2017 Aug 17;12(8):e0182786. doi: 10.1371/journal.pone.0182786. eCollection 2017.

20.

Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting.

Carbognin L, Pilotto S, Nortilli R, Brunelli M, Nottegar A, Sperduti I, Giannarelli D, Bria E, Tortora G.

Oncologist. 2016 Mar;21(3):283-91. doi: 10.1634/theoncologist.2015-0307. Epub 2016 Feb 10.

Supplemental Content

Support Center